Folate-Conjugated Rapamycin Slows Progression of Polycystic Kidney Disease

Activation of the mammalian target of rapamycin (mTOR) signaling pathway is aberrant in autosomal-dominant polycystic kidney disease (ADPKD). The mTOR inhibitors, such as rapamycin, ameliorate PKD in rodent models, but clinical trials have not shown benefit, possibly as a result of low tissue concen...

Ausführliche Beschreibung

Gespeichert in:

Bibliographische Detailangaben
Veröffentlicht in:	Journal of the American Society of Nephrology 2012-10, Vol.23 (10), p.1674-1681
Hauptverfasser:	SHILLINGFORD, Jonathan M, LEAMON, Christopher P, VLAHOV, Lontcho R, WEIMBS, Thomas
Format:	Artikel
Sprache:	eng
Schlagworte:	Animals Basic Research Biological and medical sciences Cell Line Disease Models, Animal Endocytosis Folate Receptors, GPI-Anchored - metabolism Folic Acid - analogs & derivatives Folic Acid - therapeutic use Humans Kidney - drug effects Kidney - metabolism Kidney - pathology Kidneys Malformations of the urinary system Medical sciences Mice Nephrology. Urinary tract diseases Polycystic Kidney, Autosomal Dominant - drug therapy Polycystic Kidney, Autosomal Dominant - metabolism Polycystic Kidney, Autosomal Dominant - pathology Signal Transduction - drug effects Sirolimus - analogs & derivatives Sirolimus - therapeutic use TOR Serine-Threonine Kinases - metabolism
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Schreiben Sie den ersten Kommentar!